Apolipoproteína E e Doença de Alzheimer

  • Denise Prado formação acadêmica, Mestre em Ciências Farmacêuticas, Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal.
  • Inês Lopes Cardoso Bioquímico, Professor Associado, Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Porto, Portugal.
Palavras-chave: Apolipoproteína E,, Doença de Alzheimer, Demência, Fatores de Risco, Alelos da APOE

Resumo

Contexto. A doença de Alzheimer (DA) é uma demência que afe­ta indivíduos tanto em idades avançadas como em idades precoces. Trata-se de uma doença resultante de perdas das funções neuronais cognitivas que envolve principalmente a memória. Objetivo. Neste artigo pretende-se fazer uma breve revisão bibliográfica sobre o pa­pel da apolipoproteína E (apoE) como fator de risco genético para o desenvolvimento de DA. Método. Para tal foi realizada uma revisão sistemática da literatura existente sobre o tema, tendo sido revistos 72 artigos científicos entre 1972 e 2007. Foram efetuadas pesquisas nos motores de busca da PubMed, B-on, Google Acadêmico, Me­dline e Science Direct, utilizando os unitermos: “apolipoprotein E” e “Alzheimer’s disease”. Resultados. Como resultados desta pesqui­sa verificou-se existir influência da apoE na acumulação do péptido β-amilóide e consequentemente na patogénese da DA. Foi ainda possível relacionar a presença dos diversos alelos codificantes da apoE (com localização 19q13.2) e suas combinações com um melhor ou pior prognóstico para o desenvolvimento de DA, sendo o alelo ε4 o responsável pelo aumento do risco de desenvolvimento precoce de DA. Conclusão. No entanto, esta apolipoproteína não é em si sufi­ciente para causar DA, mas promove o aumento do risco do indivíduo vir a desenvolver a doença.

Métricas

Carregando métricas...

Referências

Mestel R. Putting prions to the test. Science 1996;273:184-9. http://dx.doi.org/10.1126/science.273.5272.184

Ying W. Deleterious network hypothesis of Alzheimer’s disease. Med Hypotheses 1996;46:421-8. http://dx.doi.org/10.1016/S0306-9877(96)90021-3

Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.

Malamud D. Neuropathology of organic brain syndromes associated with aging. In: Gaitz CM. Aging and the brain, NY: Plenum Press; 1972; p.63-87. http://dx.doi.org/10.1007/978-1-4684-8503-5_6

Pericak-Vance MA, Bass MP, Yamaoka LH, Gaskell PC, Scott WK, Terwedow HA, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA 1997;278:1237-41. http://dx.doi.org/10.1001/jama.278.15.1237 http://dx.doi.org/10.1001/jama.1997.03550150041033

St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, et al. The genetic defect causing familial Alzheimer’s disease maps on chromosome 21. Science 1987;235:885-90. http://dx.doi.org/10.1126/science.2880399

Schellemberg D, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, et al. Genetic linkage evidence for a familial Alzheimer´s disease locus on chromosome 14. Science 1992;258:668-71. http://dx.doi.org/10.1126/science.1411576

Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995;269:973-7. http://dx.doi.org/10.1126/science.7638622 http://dx.doi.org/10.1126/science.7638621

Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 1998; 19:357-60. http://dx.doi.org/10.1038/1243

Papassotiropoulos A, Bagli M, Feder O, Jessen F, Maier W, Rao ML, et al. Genetic polimorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer’s disease. Neurosci Lett 1999;262:171-4. http://dx.doi.org/10.1016/S0304-3940(99)00071-3

Harman D. A hypothesis on the pathogenesis of Alzheimer’s disease. Ann N Y Acad Sci 1996;786:152-68. http://dx.doi.org/10.1111/j.1749-6632.1996.tb39059.x

Tanzi RE, Bertram L. New frontiers in Alzheimer’s disease genetics. Neuron 2001;32:181-4. http://dx.doi.org/10.1016/S0896-6273(01)00476-7

Holmes C. Genotype and phenotype in Alzheimer’s disease. Br J Psychiatry 2002;180:131-4. http://dx.doi.org/10.1192/bjp.180.2.131

Rogaeva E. The solved and unsolved mysteries of the genetics of early-onset Alzheimer’s disease. Neuromolecular Med 2002; 2:1-10. http://dx.doi.org/10.1385/NMM:2:1:01

Cacabelos R. Diagnosis of Alzheimer’s disease: defining genetic profiles (genotype vs phenotype). Acta Neurol Scand Suppl 1996; 165:72-84. http://dx.doi.org/10.1111/j.1600-0404.1996.tb05875.x

Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer’s disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003; 84:1215-36. http://dx.doi.org/10.1046/j.1471-4159.2003.01615.x

Uchida N, Ujike H, Tanaka Y, Sakai A, Yamamoto M, Fujisawa Y, et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psychiatry 2005; 13:1062-6. http://dx.doi.org/10.1176/appi.ajgp.13.12.1062 http://dx.doi.org/10.1097/00019442-200512000-00005

Monastero R, Caldarella R, Mannino M, Cefalú AB, Lopez G, Noto D, et al. Lack of association between angiotensin converting enzyme polymorphism and sporadic Alzheimer’s disease. Neurosci Lett 2002; 335:147-9. http://dx.doi.org/10.1016/S0304-3940(02)01182-5

Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Tanzi RE, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995; 82:331-40. http://dx.doi.org/10.1016/0092-8674(95)90320-8

Rogers J. An IL-1 alpha susceptibility polymorphism in Alzheimer’s disease: new fuel for the inflammation hypothesis. Neurology 2000;55:464-5. http://dx.doi.org/10.1212/WNL.55.4.464

Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-4. http://dx.doi.org/10.1016/0014-5793(91)80962-3

Paik YK, Chang DJ, Reardon CA, Davies GE, Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipoprotein E gene. Proc Natl Acad Sci USA 1985; 82:3445-9. http://dx.doi.org/10.1073/pnas.82.10.3445

Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2 and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19:472-84. http://dx.doi.org/10.1161/01.ATV.19.3.472

Bowman BH. Hepatic plasma proteins: mechanisms of function and regulation, San Diego: Academic Press Inc; 1993; p.159-67.

Smit M, van der Kooij-Meijs E, Frants RR, Havekes L, Klasen EC. Apolipoprotein gene cluster on chromosome 19: Definite localization of the APOC2 gene and the polymorphic HpaI site associated with type III hyperlipoproteinenia. Hum Genet 1988; 78:90-3. http://dx.doi.org/10.1007/BF00291243

Lin CT, Xu YF, Wu JY, Chan L. Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues. J Clin Invest 1986; 78:947-58. http://dx.doi.org/10.1172/JCI112685

Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987; 917:148-61. http://dx.doi.org/10.1016/0005-2760(87)90295-5

Nakai M, Kawamata T, Taniguchi T, Maeda K, Tanaka C. Expression of apolipoprotein E mRNA in rat microglia. Neurosci Lett 1996; 211:41-4. http://dx.doi.org/10.1016/0304-3940(96)12716-6

Beffert U, Poirier J. ApoE associated with lipid has a reduced capacity to inhibit beta-amyloid fibril formation. Neuroreport 1998; 9:3321-3. http://dx.doi.org/10.1097/00001756-199810050-00031

Lane RM, Farlow MR. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer’s disease. J Lipid Res 2005; 46:949-68. http://dx.doi.org/10.1194/jlr.M400486-JLR200

Vaya J, Schipper HM. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 2007; 102:1727-37. http://dx.doi.org/10.1111/j.1471-4159.2007.04689.x

Siest G, Pillot T, Régis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41:1068-86.

Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000;1:507-37. http://dx.doi.org/10.1146/annurev.genom.1.1.507

Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem 1999; 274:35711-8. http://dx.doi.org/10.1074/jbc.274.50.35711

Li WH, Tanimura M, Luo CC, Datta S, Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res 1988; 29:245-71.

Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor- binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257:2518-21.

Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981; 256:9077-83.

Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982; 257:4171-8.

Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet 1979; 15:63-72. http://dx.doi.org/10.1111/j.13990004.1979.tb02028.x

Martins RN, Clarnette R, Fisher C, Broe GA, Brooks WS, Montgomery P, et al. ApoE genotypes in Australia: roles in early and late onset Azheimer’s disease and Down’s syndrome. Neuroreport 1995; 6:1513-6. http://dx.doi.org/10.1097/00001756-199507310-00012

Scacchi R, Gambina G, Ruggeri M, Martini MC, Ferrari G, Silvestri M, et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer’s disease. Neurosci Lett 1999; 259:33-6. http://dx.doi.org/10.1016/S0304-3940(98)00889-1

Corbo RM, Scacchi R. Apolipoprotein E (apoE) allele distribuition in the world: is a apoE4 a “thrifty” allele? Ann Hum Genet 1999; 63:301-10. http://dx.doi.org/10.1046/j.1469-1809.1999.6340301.x

Hixson JE, Cox LA, Borenstein S. The baboon apolipoprotein E gene: structure, expression, and linkage with the gene for apolipoprotein C-1. Genomics 1988; 2:315-23. http://dx.doi.org/10.1016/0888-7543(88)90020-1

Hanlon CS, Rubinsztein DC. Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. Atherosclerosis 1995;112:85-90. http://dx.doi.org/10.1016/0021-9150(94)054025

Finch C. Toward a biology of middle age. In: Lachman ME. Handbook of Midlife Development, NY: John Wiley & Sons; 2001; p.77-108.

Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8. http://dx.doi.org/10.1001/archneur.56.3.303

Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Stopford C,et al. Apolipoprotein E epsilon4 allele frequency and age at onset of Alzheimer’s disease. Dement Geriatr Cogn Disord 2007; 23:60-6. http://dx.doi.org/10.1159/000097038

Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921-3. http://dx.doi.org/10.1126/science.8346443

Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheier disease. ProcNatl Acad Sci USA 1993;90:1977-81. http://dx.doi.org/10.1073/pnas.90.5.1977

Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak- -Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43:1467-72. http://dx.doi.org/10.1212/WNL.43.8.1467

Bales KR, Verina T, Dodel RC, Altstiel L, Bender M, Hyslop P, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263-4. http://dx.doi.org/10.1038/ng1197-263

Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the Alzgene database. Nat Genet 2007;39:17-23. http://dx.doi.org/10.1038/ng1934

Panza F, Solfrizzi V, D’Introno A, Capurso C, Colacicco AM, Torres F, et al. Genetics of late-onset Alzheimer’s disease: vascular risk and beta-amyloid metabolism. Recenti Prog Med 2002;93:489-97.

Ewbank DC. A multistate model of the genetic risk of Alzheimer’s disease. Exp Aging Res 2002;28:477-99. http://dx.doi.org/10.1080/03610730290103096

Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4. http://dx.doi.org/10.1038/ng0694-180

Roses AD, Gilbert J, Xu PT, Sullivan P, Popko B, Burkhart DS, et al. Cis-acting human ApoE tissue expression element is associated with human pattern of intraneuronal ApoE in transgenic mice. Neurobiol Aging 1998;9:S53-8. http://dx.doi.org/10.1016/S0197-4580(98)00030-X

Xu PT, Gilbert JR, Qiu HL, Ervin J, Rothrock-Christian TR, Hulette C, et al. Specific regional transcription of apolipoprotein E in human brain neurons. Am J Pathol 1999;154:601-11. http://dx.doi.org/10.1016/S00029440(10)65305-9

Boschert U, Merlo-Pich E, Higgins G, Roses AD, Catsicas S. Apolipoprotein E expression by neurons surviving excitotoxic stress. Neurobiol Dis 1999;6:508-14. http://dx.doi.org/10.1006/nbdi.1999.0251

Corder EH, Lannfelt L, Bogdanovic N, Fratiglioni L, Mori H. The role of APOE polymorphisms in late-onset dementias. Cell Mol Life Sci 1998;54:928-34. http://dx.doi.org/10.1007/s000180050223

Czyzewski K, Pfeffer A, Barcikowska M. [Apolipoprotein E function in the nervous system]. Neurol Neurochir Pol 1998;32:125-32.

Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci 2003;6:345-51. http://dx.doi.org/10.1038/nn0403-345

Acharya P, Segall ML, Zaiou M, Morrow J, Weisgraber KH, Phillips MC, et al. Comparison of the stabilities and unfolding pathways of human apolipoprotein E isoforms by differential scanning calorimetry and circular dichroism. Biochim Biophys Acta 2002;1584:9-19. http://dx.doi.org/10.1016/S1388-1981(02)00263-9

Finch CE, Sapolsky RM. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol Aging 1999;20:407-8. http://dx.doi.org/10.1016/S0197-4580(99)00053-6

Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, et al. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer’s disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci USA 2003;100:10966-71. http://dx.doi.org/10.1073/pnas.1434398100

Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer’s disease. Neurology 2003;60:246-52. http://dx.doi.org/10.1212/01.WNL.0000042478.08543.F7

Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-53. http://dx.doi.org/10.1073/pnas.90.20.9649

De Leeuw FE, Barkhof F, Scheltens P. White matter lesions and hippocampal atrophy in Alzheimer’s disease. Neurology 2004;62:310-12. http://dx.doi.org/10.1212/01.WNL.0000103289.03648.AD

Laskowitz DT, Sheng H, Bart RD, Joyner KA, Roses AD, Warner DS. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 1997;17:753-8. http://dx.doi.org/10.1097/00004647-199707000-00005

Lucotte G, Loirat F, Hazout S. Pattern of gradient of apolipoprotein E allele* 4 frequencies in western Europe. Hum Biol 1997;69:253-62. 70.Kardia SLR, Stengärd J, Templeton A. An evolutionary perspective on the

genetic architecture of susceptibility to cardiovascular disease. In: Stearns SC. Evolution in Health and Disease, Oxford: Oxford University Press; 1999; p.382-8.

Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengârd JH, et al. Apolipoprotein E variation at the sequence haloptype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000;67:881-900. http://dx.doi.org/10.1086/303070

Nickerson DA, Taylor SL, Fullerton SM, Weiss KM, Clark AG, Stengård JH, et al. Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene. Genome Res 2000;10:1532-45. http://dx.doi.org/10.1101/gr.146900

Publicado
2013-03-31
Como Citar
Prado, D., & Cardoso, I. L. (2013). Apolipoproteína E e Doença de Alzheimer. Revista Neurociências, 21(1), 118-125. https://doi.org/10.34024/rnc.2013.v21.8211
Seção
Revisão de Literatura